Recursion Pharmaceuticals Suffers Larger Drop Than Market Amid Biotech Sector's Gain

Recursion Pharmaceuticals (RXRX) shares fell 4.88% to $3.90, underperforming the S&P 500, which lost 0.51%. The biotechnology company's stock has dropped 9.89% over the past month, lagging the Medical sector's gain of 3.1%. Analysts expect a Q1 EPS of -$0.28 and Q1 revenue of $25.5 million, up 460.44% YoY. Full-year estimates call for -$1.59 EPS and $64.62 million revenue. The Zacks Rank is #2 (Buy) for RXRX.